Trial Profile
A Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Dose-Escalation, Phase 2 Study Evaluating the Safety and Tolerability of NCX 4251 (Fluticasone Propionate Nanocrystal) Ophthalmic Suspension, 0.1% QD and BID for the Treatment of Acute Exacerbations of Blepharitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jun 2023
Price :
$35
*
At a glance
- Drugs Fluticasone propionate (Primary)
- Indications Blepharitis
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms DANUBE
- Sponsors NicOx
- 13 Oct 2020 Primary endpoint has been met, according to a NicOx media release.
- 08 Apr 2020 According to a NicOx media release, the company has held a Type C meeting with the U.S. Food and Drug Administration (FDA) in which the data from this study was reviewed and the next NCX 4251 trial designs were discussed.
- 06 Mar 2020 According to a NicOx media release, NCX 4251 Danube Phase 2 results were presented at American Glaucoma Society (February 27 to March 1, 2020)